Prime Medicine clears legal hurdle with Beam Therapeutics, moves AATD gene therapy toward clinic

Prime Medicine announced it will advance its AATD gene editing candidate into clinical trials after arbitrators ruled in its favor in a dispute with Beam Therapeutics.

The dispute centered on a 2019 contract between the two companies, which Beam argued limited Prime's ability to develop the candidate. Arbitrators concluded the agreement did not bar Prime's progress.

The decision removes a legal obstacle, allowing Prime Medicine to focus on preclinical work and regulatory filings for the therapy targeting alpha‑1 antitrypsin deficiency.

The outcome may influence future collaborations and contract negotiations among gene‑editing firms.